查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1604587

抗病毒藥物市場：按藥物類型、治療方法和最終用途 - 2025-2030 年全球預測

Antiviral Drugs Market by Drug Type (Branded Drugs, Generic Drugs), Therapeutics (Acquired Immunodeficiency Syndrome Therapeutics, Hepatitis (B & C) Therapeutics, Herpes Therapeutics), End Use - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年抗病毒藥物市值為562.2億美元，預計2024年將達到598.4億美元，複合年成長率為6.54%，到2030年將達到876.1億美元。

抗病毒藥物是一種旨在抑制病毒感染發生和傳播的藥物。其範圍涵蓋多種應用，包括治療愛滋病毒、肝炎、流感和其他傳染性病毒性疾病。對抗病毒藥物的需求源自於控制和預防疫情、保護弱勢族群、確保公共衛生安全的需求。在 COVID-19 和其他新興病毒威脅的背景下，對有效抗病毒藥物的需求激增，凸顯了它們在醫療保健中的關鍵作用。最終用途範圍包括醫院、診所、實驗室和居家照護場所，用於治療和預防目的。

主要市場統計
基準年[2023] 562.2億美元
預計年份 [2024] 598.4億美元
預測年份 [2030] 876.1億美元
複合年成長率（%） 6.54%

推動市場成長的主要因素包括持續的研究和技術進步、對病毒感染的認知不斷提高以及政府和私營部門投資的增加。強大的在研藥物和新株的頻繁出現為市場拓展提供了潛在的機會。公司可以透過加速藥物開發過程並應對快速變化的病毒動態來利用這些優勢。然而，市場面臨高成本、監管挑戰和潛在病毒抗藥性等限制，阻礙了抗病毒治療的廣泛使用和可及性。

創新的機會在於個人化醫療，即根據個別患者的需求定製藥物，以及開發可同時針對多種病毒的頻譜抗病毒藥物。此外，在藥物發現中使用人工智慧和機器學習有可能加速有效化合物的識別。抗病毒藥物市場是一個充滿活力的市場，其特點是不斷的研發努力和快速的技術進步。公司必須保持敏捷性，以適應不斷變化的監管標準和新的健康威脅。透過投資創新解決方案和策略聯盟，公司可以加速成長，同時滿足有效抗病毒療法的迫切需求。

市場動態：揭示快速發展的抗病毒藥物市場的關鍵市場洞察

供需的動態交互作用正在改變抗病毒藥物市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助消費行為及其對製造業的影響。

  • 市場促進因素
    • HIV、肝炎和流感等病毒性疾病增加
    • 政府和私營部門在抗病毒藥物開發方面的支出增加
    • 增加抗病毒計劃和宣傳活動以提高客戶意識
  • 市場限制因素
    • 對治療成本上升和抗病毒藥物專利到期的擔憂
  • 市場機會
    • 針對多種病毒感染疾病和疾病的疫苗生產的研究和開發
    • HIV 疫苗開發的廣泛配方
  • 市場挑戰
    • 同類療法等替代療法的普及

波特五力：駕馭抗病毒藥物市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解抗病毒藥物市場的外部影響

外部宏觀環境因素在塑造抗病毒藥物市場的表現動態中發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解抗病毒藥物市場競爭狀況

抗病毒藥物市場的詳細市場佔有率分析可以對供應商的業績進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV定位矩陣抗病毒藥物市場供應商績效評估

FPNV定位矩陣是評估抗病毒藥物市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議描繪抗病毒藥物市場的成功之路

抗病毒藥物市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • HIV、肝炎和流感等病毒性疾病的發生率增加
      • 政府和私營部門在抗病毒藥物開發方面的支出增加
      • 增加防毒計畫和宣傳活動以提高客戶意識
    • 抑制因素
      • 抗病毒藥物治療費用高及專利到期的擔憂
    • 機會
      • 針對多種病毒感染疾病和疾病的疫苗生產的研究和開發
      • HIV 疫苗開發的廣泛配方
    • 任務
      • 同類療法等替代療法的普及
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章 抗病毒藥物市場（依藥物類型）

  • 品牌藥品
  • 學名藥

第7章 抗病毒藥物市場治療

  • 治療後天免疫力缺乏的藥物
  • 肝炎（乙型和丙型）治療藥物
  • 皰疹治療藥
  • 流感治療藥物
  • 肺炎

第8章抗病毒藥物市場：依最終用途

  • 門診手術中心
  • 診所
  • 醫院

第9章美洲抗病毒藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區抗病毒藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲抗病毒藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Abacus Bioscience Inc.
  • Abbott Laboratories
  • AbbVie Inc.
  • Antiva Biosciences, Inc.
  • AstraZeneca PLC
  • Aurobindo Pharma
  • Bristol-Myers Squibb Company
  • Chimerix Inc.
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • ENYO Pharma SA
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
Product Code: MRR-4358BACA8289

The Antiviral Drugs Market was valued at USD 56.22 billion in 2023, expected to reach USD 59.84 billion in 2024, and is projected to grow at a CAGR of 6.54%, to USD 87.61 billion by 2030.

Antiviral drugs are pharmaceuticals designed to inhibit the development and spread of viral infections. Their scope encompasses several applications, including treating conditions like HIV, hepatitis, influenza, and other contagious viral diseases. The necessity for antiviral drugs arises from the need to control and prevent outbreaks, protect susceptible populations, and ensure public health safety. In the context of COVID-19 and other emerging viral threats, the demand for effective antiviral medications has surged, underscoring their critical role in healthcare. The end-use scope includes hospitals, clinics, research laboratories, and home care settings, where antiviral drugs serve both therapeutic and preventive purposes.

KEY MARKET STATISTICS
Base Year [2023] USD 56.22 billion
Estimated Year [2024] USD 59.84 billion
Forecast Year [2030] USD 87.61 billion
CAGR (%) 6.54%

Key factors driving the market growth include ongoing research and technological advancements, rising awareness about viral infections, and increasing government and private sector investments. Robust pipeline drugs and the frequent emergence of new viral strains present potential opportunities for market expansion. Companies can capitalize on these by accelerating drug development processes and adapting to rapid changes in viral dynamics. However, the market faces limitations such as high costs, regulatory challenges, and the potential for viral resistance, which can impede widespread adoption and accessibility of antiviral treatments.

Innovation opportunities lie in personalized medicine, where drugs are tailored to individual patient needs, and in developing broad-spectrum antivirals that can target multiple viruses simultaneously. Additionally, leveraging artificial intelligence and machine learning for drug discovery could accelerate the identification of effective compounds. The antiviral drug market is dynamic, characterized by continuous R&D endeavors and rapid technological advancements. Companies must maintain agility to adapt to changing regulatory standards and emerging health threats. By investing in innovative solutions and strategic collaborations, businesses can drive growth while meeting the pressing need for effective antiviral therapies.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Antiviral Drugs Market

The Antiviral Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing occurrence of viral diseases such as HIV, hepatitis, and influenza
    • Rising government and private sector expenditure in the development of antiviral drugs
    • Growing number of antiviral programs and campaigns to increase customer awareness
  • Market Restraints
    • High cost of antiviral drug treatment and concerns of patent expiration
  • Market Opportunities
    • Research and development in the production of vaccines for numerous viral infections and diseases
    • Extensive formulations to develop HIV vaccines
  • Market Challenges
    • Prevalence of alternative therapy such as homeopathy

Porter's Five Forces: A Strategic Tool for Navigating the Antiviral Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Antiviral Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Antiviral Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Antiviral Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Antiviral Drugs Market

A detailed market share analysis in the Antiviral Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Antiviral Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Antiviral Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Antiviral Drugs Market

A strategic analysis of the Antiviral Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Antiviral Drugs Market, highlighting leading vendors and their innovative profiles. These include Abacus Bioscience Inc., Abbott Laboratories, AbbVie Inc., Antiva Biosciences, Inc., AstraZeneca PLC, Aurobindo Pharma, Bristol-Myers Squibb Company, Chimerix Inc., Cipla Limited, Dr. Reddy's Laboratories Ltd., ENYO Pharma SA, F. Hoffmann-La Roche AG, Gilead Sciences, Inc., GlaxoSmithKline PLC, Johnson & Johnson, Merck & Co., Inc., and Novartis AG.

Market Segmentation & Coverage

This research report categorizes the Antiviral Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Type, market is studied across Branded Drugs and Generic Drugs.
  • Based on Therapeutics, market is studied across Acquired Immunodeficiency Syndrome Therapeutics, Hepatitis (B & C) Therapeutics, Herpes Therapeutics, Influenza Therapeutics, and Pneumonia.
  • Based on End Use, market is studied across Ambulatory Surgical Centres, Clinics, and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing occurrence of viral diseases such as HIV, hepatitis, and influenza
      • 5.1.1.2. Rising government and private sector expenditure in the development of antiviral drugs
      • 5.1.1.3. Growing number of antiviral programs and campaigns to increase customer awareness
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of antiviral drug treatment and concerns of patent expiration
    • 5.1.3. Opportunities
      • 5.1.3.1. Research and development in the production of vaccines for numerous viral infections and diseases
      • 5.1.3.2. Extensive formulations to develop HIV vaccines
    • 5.1.4. Challenges
      • 5.1.4.1. Prevalence of alternative therapy such as homeopathy
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Antiviral Drugs Market, by Drug Type

  • 6.1. Introduction
  • 6.2. Branded Drugs
  • 6.3. Generic Drugs

7. Antiviral Drugs Market, by Therapeutics

  • 7.1. Introduction
  • 7.2. Acquired Immunodeficiency Syndrome Therapeutics
  • 7.3. Hepatitis (B & C) Therapeutics
  • 7.4. Herpes Therapeutics
  • 7.5. Influenza Therapeutics
  • 7.6. Pneumonia

8. Antiviral Drugs Market, by End Use

  • 8.1. Introduction
  • 8.2. Ambulatory Surgical Centres
  • 8.3. Clinics
  • 8.4. Hospitals

9. Americas Antiviral Drugs Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Antiviral Drugs Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Antiviral Drugs Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abacus Bioscience Inc.
  • 2. Abbott Laboratories
  • 3. AbbVie Inc.
  • 4. Antiva Biosciences, Inc.
  • 5. AstraZeneca PLC
  • 6. Aurobindo Pharma
  • 7. Bristol-Myers Squibb Company
  • 8. Chimerix Inc.
  • 9. Cipla Limited
  • 10. Dr. Reddy's Laboratories Ltd.
  • 11. ENYO Pharma SA
  • 12. F. Hoffmann-La Roche AG
  • 13. Gilead Sciences, Inc.
  • 14. GlaxoSmithKline PLC
  • 15. Johnson & Johnson
  • 16. Merck & Co., Inc.
  • 17. Novartis AG

LIST OF FIGURES

  • FIGURE 1. ANTIVIRAL DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. ANTIVIRAL DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ANTIVIRAL DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. ANTIVIRAL DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ANTIVIRAL DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANTIVIRAL DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY BRANDED DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY GENERIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY ACQUIRED IMMUNODEFICIENCY SYNDROME THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HEPATITIS (B & C) THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HERPES THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INFLUENZA THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY PNEUMONIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTRES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 147. ANTIVIRAL DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 148. ANTIVIRAL DRUGS MARKET, FPNV POSITIONING MATRIX, 2023